Elezanumab + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Spinal Cord Injury (SCI)

Conditions

Spinal Cord Injury (SCI)

Trial Timeline

Sep 6, 2020 → Jan 26, 2026

NCT ID

NCT04295538

About Elezanumab + Placebo

Elezanumab + Placebo is a phase 2 stage product being developed by AbbVie for Spinal Cord Injury (SCI). The current trial status is completed. This product is registered under clinical trial identifier NCT04295538. Target conditions include Spinal Cord Injury (SCI).

What happened to similar drugs?

7 of 20 similar drugs in Spinal Cord Injury (SCI) were approved

Approved (7) Terminated (1) Active (12)

🔄Ropivacaine + BupivacaineAstraZenecaPhase 3

🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3

✅Onasemnogene Abeparvovec-brveNovartisApproved

🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3

🔄onasemnogene abeparvovecNovartisPhase 3

🔄onasemnogene abeparvovec-xioiNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04309474	Phase 2	Completed	Nov 9, 2020	Dec 23, 2024	Acute Ischemic Stroke
NCT04295538	Phase 2	Completed	Sep 6, 2020	Jan 26, 2026	Spinal Cord Injury (SCI)
NCT03737812	Phase 2	Completed	Feb 27, 2019	Aug 30, 2021	Multiple Sclerosis (MS)
NCT03737851	Phase 2	Completed	Dec 11, 2018	Sep 9, 2021	Multiple Sclerosis (MS)

Competing Products

20 competing products in Spinal Cord Injury (SCI)

See all competitors

Product	Company	Stage	Hype Score
SUN13837 injection + Placebo	Daiichi Sankyo	Phase 2	35
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg	Astellas Pharma	Phase 2	35
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells	Sun Pharmaceutical	Phase 2	42
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells	Sun Pharmaceutical	Phase 1	36
Elezanumab	AbbVie	Pre-clinical	30
Ropivacaine + Bupivacaine	AstraZeneca	Phase 3	40
Onasemnogene Abeparvovec-xioi	Novartis	Phase 1	21
Zolgensma	Novartis	Pre-clinical	33
BVS857 + Placebo	Novartis	Phase 2	35
AVXS-101	Novartis	Phase 1	29
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	44
Onasemnogene Abeparvovec-brve	Novartis	Approved	50
Onasemnogene Abeparvovec-xioi	Novartis	Pre-clinical	30
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	40
branaplam	Novartis	Phase 1/2	32
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	40
onasemnogene abeparvovec	Novartis	Phase 3	47
onasemnogene abeparvovec-xioi	Novartis	Phase 3	40
Risdiplam	Roche	Phase 1	29
ATI355	Novartis	Phase 1	29